# SLB Limited: financial statements, quarterly SLB · NYSE · CIK 87347 · [Energy](/sectors/energy.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/slb.md) · [Financials](/companies/slb/financials.md) · [Filings](/companies/slb/filings.md) · [Insiders](/companies/slb/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/slb/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [8,990 d](/filings/0001193125-26-021017.md) | [8,707](/filings/0000950170-25-058413.md) | [9,139](/filings/0000950170-25-098217.md) | [9,159](/filings/0001193125-25-246028.md) | [9,284 d](/filings/0001193125-26-021017.md) | [8,490](/filings/0001193125-26-190101.md) | [8,546](/filings/0001193125-26-322595.md) | [8,928](/filings/0001193125-26-435577.md) | [9,745 d](/filings/0001193125-26-021017.md) | [8,721](/filings/0001193125-26-190101.md) | [8,972](/filings/0001193125-26-322595.md) | [9,449](/filings/0001193125-26-435577.md) | | Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Research and development | $m | [187 d](/filings/0001193125-26-021017.md) | [182](/filings/0000950170-25-058413.md) | [188](/filings/0000950170-25-098217.md) | [187](/filings/0001193125-25-246028.md) | [192 d](/filings/0001193125-26-021017.md) | [172](/filings/0001193125-26-190101.md) | [180](/filings/0001193125-26-322595.md) | [170](/filings/0001193125-26-435577.md) | [187 d](/filings/0001193125-26-021017.md) | [164](/filings/0001193125-26-190101.md) | [171](/filings/0001193125-26-322595.md) | [156](/filings/0001193125-26-435577.md) | | Operating income | $m | [1,868 d](/filings/0000950170-24-006884.md) | [1,649](/filings/0000950170-24-047250.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Interest expense | $m | [130 d](/filings/0001193125-26-021017.md) | [113](/filings/0000950170-25-058413.md) | [132](/filings/0000950170-25-098217.md) | [136](/filings/0001193125-25-246028.md) | [131 d](/filings/0001193125-26-021017.md) | [147](/filings/0001193125-26-190101.md) | [142](/filings/0001193125-26-322595.md) | [142](/filings/0001193125-26-435577.md) | [126 d](/filings/0001193125-26-021017.md) | [116](/filings/0001193125-26-190101.md) | [128](/filings/0001193125-26-322595.md) | [133](/filings/0001193125-26-435577.md) | | Income tax | $m | [285 d](/filings/0001193125-26-021017.md) | [259](/filings/0000950170-25-058413.md) | [276](/filings/0000950170-25-098217.md) | [289](/filings/0001193125-25-246028.md) | [269 d](/filings/0001193125-26-021017.md) | [234](/filings/0001193125-26-190101.md) | [237](/filings/0001193125-26-322595.md) | [226](/filings/0001193125-26-435577.md) | [143 d](/filings/0001193125-26-021017.md) | [195](/filings/0001193125-26-190101.md) | [204](/filings/0001193125-26-322595.md) | [239](/filings/0001193125-26-435577.md) | | Net income | $m | [1,112 d](/filings/0001193125-26-021017.md) | [1,068](/filings/0000950170-25-058413.md) | [1,112](/filings/0000950170-25-098217.md) | [1,186](/filings/0001193125-25-246028.md) | [1,095 d](/filings/0001193125-26-021017.md) | [797](/filings/0001193125-26-190101.md) | [1,014](/filings/0001193125-26-322595.md) | [739](/filings/0001193125-26-435577.md) | [824 d](/filings/0001193125-26-021017.md) | [752](/filings/0001193125-26-190101.md) | [786](/filings/0001193125-26-322595.md) | [735](/filings/0001193125-26-435577.md) | | Diluted EPS | $ per share | not reported | [0.74](/filings/0000950170-25-058413.md) | [0.77](/filings/0000950170-25-098217.md) | [0.83](/filings/0001193125-25-246028.md) | not reported | [0.58](/filings/0001193125-26-190101.md) | [0.74](/filings/0001193125-26-322595.md) | [0.50](/filings/0001193125-26-435577.md) | not reported | [0.50](/filings/0001193125-26-190101.md) | [0.52](/filings/0001193125-26-322595.md) | [0.49](/filings/0001193125-26-435577.md) | | Basic EPS | $ per share | not reported | [0.75](/filings/0000950170-25-058413.md) | [0.78](/filings/0000950170-25-098217.md) | [0.84](/filings/0001193125-25-246028.md) | not reported | [0.58](/filings/0001193125-26-190101.md) | [0.75](/filings/0001193125-26-322595.md) | [0.50](/filings/0001193125-26-435577.md) | not reported | [0.50](/filings/0001193125-26-190101.md) | [0.53](/filings/0001193125-26-322595.md) | [0.50](/filings/0001193125-26-435577.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: not reported - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [2.9](/filings/0000950170-25-007638.md) | [2.8](/filings/0000950170-24-047250.md) | [3.0](/filings/0000950170-24-085905.md) | [3.1](/filings/0000950170-24-116535.md) | [3.5](/filings/0001193125-26-021017.md) | [2.9](/filings/0000950170-25-058413.md) | [3.2](/filings/0000950170-25-098217.md) | [3.0](/filings/0001193125-25-246028.md) | [3.0](/filings/0001193125-26-435577.md) | [2.8](/filings/0001193125-26-190101.md) | [2.7](/filings/0001193125-26-322595.md) | [2.6](/filings/0001193125-26-435577.md) | | Current assets | $bn | [17.7](/filings/0000950170-25-007638.md) | [17.7](/filings/0000950170-24-047250.md) | [18.5](/filings/0000950170-24-085905.md) | [18.8](/filings/0000950170-24-116535.md) | [18.6](/filings/0001193125-26-021017.md) | [18.6](/filings/0000950170-25-058413.md) | [18.5](/filings/0000950170-25-098217.md) | [19.5](/filings/0001193125-25-246028.md) | [19.5](/filings/0001193125-26-435577.md) | [19.3](/filings/0001193125-26-190101.md) | [20.2](/filings/0001193125-26-322595.md) | [20.5](/filings/0001193125-26-435577.md) | | Total assets | $bn | [48.0](/filings/0001193125-26-021017.md) | [47.9](/filings/0000950170-24-047250.md) | [49.4](/filings/0000950170-24-085905.md) | [49.8](/filings/0000950170-24-116535.md) | [48.9](/filings/0001193125-26-021017.md) | [49.0](/filings/0000950170-25-058413.md) | [48.8](/filings/0000950170-25-098217.md) | [55.1](/filings/0001193125-25-246028.md) | [54.9](/filings/0001193125-26-435577.md) | [54.5](/filings/0001193125-26-190101.md) | [55.5](/filings/0001193125-26-322595.md) | [56.2](/filings/0001193125-26-435577.md) | | Current liabilities | $bn | [13.4](/filings/0000950170-25-007638.md) | [12.9](/filings/0000950170-24-047250.md) | [12.4](/filings/0000950170-24-085905.md) | [12.7](/filings/0000950170-24-116535.md) | [12.8](/filings/0001193125-26-021017.md) | [15.0](/filings/0000950170-25-058413.md) | [14.0](/filings/0000950170-25-098217.md) | [14.0](/filings/0001193125-25-246028.md) | [14.7](/filings/0001193125-26-435577.md) | [14.4](/filings/0001193125-26-190101.md) | [14.1](/filings/0001193125-26-322595.md) | [14.8](/filings/0001193125-26-435577.md) | | Total liabilities | $bn | [26.6](/filings/0000950170-25-007638.md) | [25.9](/filings/0000950170-24-047250.md) | [27.1](/filings/0000950170-24-085905.md) | [27.0](/filings/0000950170-24-116535.md) | [26.6](/filings/0001193125-26-021017.md) | [28.3](/filings/0000950170-25-058413.md) | [27.2](/filings/0000950170-25-098217.md) | [28.2](/filings/0001193125-25-246028.md) | [27.6](/filings/0001193125-26-435577.md) | [27.2](/filings/0001193125-26-190101.md) | [28.3](/filings/0001193125-26-322595.md) | [29.0](/filings/0001193125-26-435577.md) | | Long-term debt | $bn | [10.8](/filings/0000950170-25-007638.md) | [10.7](/filings/0000950170-24-047250.md) | [12.2](/filings/0000950170-24-085905.md) | [11.9](/filings/0000950170-24-116535.md) | [11.0](/filings/0001193125-26-021017.md) | [10.5](/filings/0000950170-25-058413.md) | [10.9](/filings/0000950170-25-098217.md) | [10.8](/filings/0001193125-25-246028.md) | [9.7](/filings/0001193125-26-435577.md) | [9.7](/filings/0001193125-26-190101.md) | [11.1](/filings/0001193125-26-322595.md) | [11.1](/filings/0001193125-26-435577.md) | | Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $bn | [20.2](/filings/0000950170-25-007638.md) | [20.7](/filings/0000950170-24-047250.md) | [21.1](/filings/0000950170-24-085905.md) | [21.5](/filings/0000950170-24-116535.md) | [21.1](/filings/0001193125-26-021017.md) | [19.5](/filings/0000950170-25-058413.md) | [20.3](/filings/0000950170-25-098217.md) | [25.6](/filings/0001193125-25-246028.md) | [26.1](/filings/0001193125-26-435577.md) | [26.2](/filings/0001193125-26-190101.md) | [26.1](/filings/0001193125-26-322595.md) | [26.1](/filings/0001193125-26-435577.md) | - Cash and equivalents: us-gaap:Cash - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: not reported - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [3,022 d](/filings/0001193125-26-021017.md) | [327](/filings/0000950170-25-058413.md) | [1,436 d](/filings/0000950170-25-098217.md) | [2,449 d](/filings/0001193125-25-246028.md) | [2,390 d](/filings/0001193125-26-021017.md) | [660](/filings/0001193125-26-190101.md) | [1,142 d](/filings/0001193125-26-322595.md) | [1,682 d](/filings/0001193125-26-435577.md) | [3,005 d](/filings/0001193125-26-021017.md) | [487](/filings/0001193125-26-190101.md) | [1,359 d](/filings/0001193125-26-322595.md) | [1,510 d](/filings/0001193125-26-435577.md) | | Capital expenditure | $m | [594 d](/filings/0001193125-26-021017.md) | [399](/filings/0000950170-25-058413.md) | [463 d](/filings/0000950170-25-098217.md) | [460 d](/filings/0001193125-25-246028.md) | [609 d](/filings/0001193125-26-021017.md) | [398](/filings/0001193125-26-190101.md) | [371 d](/filings/0001193125-26-322595.md) | [409 d](/filings/0001193125-26-435577.md) | [516 d](/filings/0001193125-26-021017.md) | [343](/filings/0001193125-26-190101.md) | [459 d](/filings/0001193125-26-322595.md) | [485 d](/filings/0001193125-26-435577.md) | | Dividends paid | $m | [356 d](/filings/0001193125-26-021017.md) | [357](/filings/0000950170-25-058413.md) | [394 d](/filings/0000950170-25-098217.md) | [393 d](/filings/0001193125-25-246028.md) | [389 d](/filings/0001193125-26-021017.md) | [386](/filings/0001193125-26-190101.md) | [387 d](/filings/0001193125-26-322595.md) | [403 d](/filings/0001193125-26-435577.md) | [426 d](/filings/0001193125-26-021017.md) | [426](/filings/0001193125-26-190101.md) | [440 d](/filings/0001193125-26-322595.md) | [439 d](/filings/0001193125-26-435577.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [1,446](/filings/0000950170-24-047250.md) | [1,442](/filings/0000950170-24-085905.md) | [1,442](/filings/0000950170-24-116535.md) | [1,447](/filings/0000950170-25-058413.md) | [1,443](/filings/0000950170-25-098217.md) | [1,432](/filings/0001193125-25-246028.md) | [1,380](/filings/0001193125-26-190101.md) | [1,366](/filings/0001193125-26-322595.md) | [1,488](/filings/0001193125-26-435577.md) | [1,515](/filings/0001193125-26-190101.md) | [1,506](/filings/0001193125-26-322595.md) | [1,497](/filings/0001193125-26-435577.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 1,476,029,613 at 2026-09-30, from the cover of the [10-Q filed 2026-10-28](/filings/0001193125-26-435577.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 05:05 ET. No prices; not investment advice.